38 studies found for:    " December 15, 2010":" January 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Withdrawn A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: 200mg [14C]- GSK2248761
22 Completed
Has Results
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
Condition: HIV
Intervention: Drug: HIV therapy
23 Completed Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients
Conditions: Flat Warts (Diagnosis);   HIV Infections
Intervention: Drug: Glycolic acid
24 Active, not recruiting TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV
Condition: HIV-1 Infections
Interventions: Drug: Darunavir;   Drug: ritonavir
25 Unknown  Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
Conditions: HIV Infections;   Liver Toxicity;   Hepatitis Co-infection
Intervention:
26 Active, not recruiting Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
Condition: Tuberculosis
Interventions: Biological: GSK's investigational vaccine 692342;   Biological: Physiological saline
27 Not yet recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
28 Completed Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
Condition: HIV
Intervention: Drug: Emtricitabine/tenofovir
29 Completed A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Condition: HIV
Interventions: Drug: TMC278;   Drug: Efavirenz
30 Completed
Has Results
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
Condition: HIV
Interventions: Drug: Tenofovir/emtricitabine;   Drug: Tenofovir/emtricitabine/efavirenz;   Drug: Raltegravir
31 Completed Recovery Management Intervention in China
Conditions: Methadone;   HIV Infections
Intervention: Behavioral: Recovery management
32 Withdrawn Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.
Conditions: HIV Infections;   Healthy
Interventions: Drug: BI 224436;   Drug: Placebo
33 Completed Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients
Condition: HIV-1
Interventions: Drug: Darunavir / Ritonavir + Tenofovir / Emtricitabine;   Drug: Atazanavir / Ritonavir + Tenofovir / Emtricitabine
34 Active, not recruiting Study of Options for Second-Line Effective Combination Therapy (SELECT)
Condition: HIV-1 Infection
Interventions: Drug: Lopinavir/ritonavir;   Drug: Raltegravir;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Abacavir/lamivudine/zidovudine;   Drug: Abacavir/lamivudine;   Drug: Lamivudine/zidovudine;   Drug: Abacavir;   Drug: Zidovudine;   Drug: Lamivudine
35 Unknown  Influence of Nevirapine on HCV Viral Load
Conditions: HCV Infection.;   HCV Viral Load.
Interventions: Drug: Nevirapine;   Drug: efavirenz, protease inhibitors
36 Enrolling by invitation Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
Condition: Kaposi's Sarcoma
Intervention: Drug: Maraviroc
37 Completed Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures
Condition: Topical Penile Exposures
Interventions: Drug: dapivirine;   Drug: matched placebo;   Drug: universal placebo
38 Terminated Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
Conditions: Lymphoma;   Nonneoplastic Condition
Interventions: Genetic: DNA analysis;   Genetic: RNA analysis;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-38) Next Page   
Indicates status has not been verified in more than two years